How much funding has Insilico Medicine raised?

Insilico Medicine has raised $632.8M in total funding, most recently a Series E round.

Who are Insilico Medicine's investors?

Insilico Medicine's investors include Warburg Pincus, OrbiMed, F-Prime Capital, B Capital Group, Qiming VP, Deerfield Management.

When was Insilico Medicine founded?

Insilico Medicine was founded in 2014.

Where is Insilico Medicine headquartered?

Insilico Medicine is headquartered in Hong Kong, Hong Kong.

What industry is Insilico Medicine in?

Insilico Medicine operates in Artificial Intelligence, Biotech, Healthcare.

How many employees does Insilico Medicine have?

Insilico Medicine has 201-500 employees.

Insilico Medicine

IPO

Generative AI and Automation for Longevity and Sustainability

Public · Hong Kong, Hong Kong · Founded 2014 · $632.8M raised

Artificial Intelligence

Biotech

Healthcare

Headquarters: Hong Kong
Employees: 201–500
Founded: 2014
Business Model: B2B
Website: insilico.com

Total Funding: $632.8M
Last Round: $123.0M Series EMar 2026
Rounds: 9
Type: Public

About

Insilico Medicine develops breakthrough solutions using generative artificial intelligence to accelerate drug discovery and development for diseases like cancer, fibrosis, immunity, and CNS disorders. The company aims to extend healthy productive longevity by reducing time and cost in bringing life-saving medications to patients. Platforms include Chemistry42, Biology42, and Pharma.ai.

Summary

Insilico Medicine is an Artificial Intelligence company based in Hong Kong, Hong Kong, founded in 2014. It has raised $632.8M in total across 9 rounds, most recently a $123.0M Series E round in Mar 2026. Investors include Warburg Pincus, OrbiMed and F-Prime Capital.

LinkedIn X (Twitter)GitHub